3 Australian Growth Stocks With Revenue Growth Up To 37%

AI chip demand is roaring, with Samsung reporting a very large jump in profit as clients rush to secure hardware for data hungry models. That kind of spending shines a light on Australian businesses with strong growth potential where insiders also own a big chunk of the register. This article walks through three such fast growing, high conviction stocks and explains why they deserve a closer look now.

The three stocks below are just a small sample. The full screen surfaces 111 more businesses where rapid growth potential sits alongside meaningful insider ownership and equally compelling narratives that are not covered here. If you want to identify and analyze the broader opportunity set, go straight to the Fast Growing Stocks With High Insider Ownership screener.

Mesoblast (ASX:MSB)

Overview: Mesoblast develops regenerative medicine therapies using mesenchymal lineage cells, focusing on late-stage treatments for severe inflammatory and cardiovascular diseases.

Operations: Mesoblast reports about $120 million in revenue from the development and commercialization of its allogeneic cellular medicines platform.

Market Cap: A$2.6 billion

Mesoblast fits this screener because its late-stage cell therapy pipeline gives management and analysts a clear growth story to lean into.

"The first and only FDA approved mesenchymal stromal cell product in the U.S., Ryoncil, together with over 1,100 patents and established commercial scale manufacturing, positions Mesoblast to benefit if cell therapies gain wider medical adoption."

What happens to margins and funding needs will hinge on how one unresolved regulatory and payer sensitivity ultimately breaks.

That regulatory swing factor is exactly what shapes the risk and upside story in the full narrative for Mesoblast, including how funding pressure could shift if approval momentum accelerates.

Telix Pharmaceuticals (ASX:TLX)

Overview: Telix Pharmaceuticals develops and commercialises radiopharmaceutical therapies and precision imaging agents, with late-stage prostate cancer programs anchoring its growth narrative.

Operations: Telix records about $705 million from Precision Medicine and $277 million from Manufacturing Solutions, with most revenue generated in the United States.

Market Cap: A$5.4 billion

Telix Pharmaceuticals matters for this screener because its Phase 3 oncology programs are backed by management that is clearly leaning into high conviction, late-stage radiopharmaceutical bets that tie directly to revenue producing diagnostics.

"Their primary revenue generating imaging agents: 'Illuccix' and 'Gozellix', are utilised in 23+ countries worldwide, including key markets such as the U.S, Europe, China and Japan, with revenue figures of $803.8m (USD) in the 2025 Financial Year.

What happens to both pricing power and earnings momentum now largely depends on how one high stakes late-stage decision point ultimately resolves.

That turning point is exactly what the full narrative for Telix Pharmaceuticals unpacks, including where current earnings could be masking either accelerating upside or brewing risk.

Codan (ASX:CDA)

Overview: Codan develops communications systems and metal detectors, with its Minelab prospecting products giving direct exposure to growing gold and recreational detection demand.

Operations: Codan generates about A$506 million from Communications and A$362 million from Metal Detection across customers in the US, UAE and other regions.

Market Cap: A$11.9 billion

Codan is included in this screener because its metal detection arm is directly linked to growth in small-scale mining and prospecting, while management confidence in communications demand provides an additional driver for the business.

"Heightened geopolitical tensions, increased defense spending, and the need for resilient communications infrastructure, especially in light of remilitarization and growing demand for unmanned systems, are associated with an expanding customer base and forward order book in defense and public safety."

What happens to Codan’s earnings trajectory now depends on how pressure around future contract quality and pricing ultimately resolves.

If you want to see how that contract risk could be masking a much bigger opportunity, read the full narrative for Codan to explore what might really be accelerating under the surface.

Seeking Alternatives Before Momentum Flies

Fresh ideas move first. Once momentum builds, prices can move fast and the best entry points can be difficult to find. Scan these under the radar lists and consider acting before that happens.

• Explore reliable income streams before yields start dropping by scanning the 5 dividend fortresses that focus on consistent payouts and balance sheet strength.
• Identify early AI leaders while they are still under the radar by running through the curated 35 profitable AI stocks that aren't just burning cash that already generate real earnings.
• Review opportunities ahead of potential power grid developments by checking the specialist 43 power grid technology and infrastructure stocks featuring businesses tied to grid upgrades and electrification activity.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com